BioInvent has signed a clinical supply agreement with AstraZeneca to assess BI-1206 + rituximab and Calquence in the P-/IIa trial for the treatment of non-Hodgkin’s lymphoma
As per the agreement, AstraZeneca will supply Calquence for its use in combination with BI-1206 + rituximab in the P-/IIa study to treat follicular lymphoma patients who have progressed or are refractory to rituximab
Furthermore, the P-I part of BI-1206 (IV) is completed & showed favorable efficacy, P-IIa dose expansion arm is ongoing and plans to recruit patients for the triplet arm & the Calquence expansion arm aims to enroll ~30 patients at multiple sites. Simultaneously, an SC formulation is underway for the treatment
Ref: BioInvent | Image: AstraZeneca
Related News:- Exelixis Entered into an Option and License Agreement with BioInvent to Develop Novel Antibody-Based Immuno-Oncology Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
